We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Maryland-based Emergent BioSolutions was the government’s highest-paid drug or vaccine vendor as of mid-June at $643 million, out of nearly $9 billion issued by HHS for COVID-19, according to a new report released yesterday by the Government Accountability Office (GAO). Read More
Sanofi and GlaxoSmithKline have reached a deal with the British government that will secure up to 60 million doses of the drugmakers’ experimental COVID-19 vaccine for the UK. Read More
Roche’s rheumatoid arthritis blockbuster Actemra (tocilizumab) showed no benefit for hospitalized COVID-19 patients in a phase 3 trial, but the company still has high hopes for the drug as a potential treatment for COVID-19 infections. Read More
The agency said the mock datasets will “support bringing safe products to market sooner” so patients can benefit from the latest technical advances. Read More
Two Democratic lawmakers called on the Government Accountability Office to review the federal government’s investment into research and development of Gilead Sciences’ remdesivir for treatment of COVID-19. Read More
Senate Republicans have proposed a COVID-19 relief package that includes $20 billion for HHS’ Biomedical Advanced Research and Development Authority for COVID-19 vaccines and therapeutics. Read More